| Date | Title | Description |
| 15.01.2025 | Be Bio Closes $92M Series C Financing | Be Bio, a Cambridge, MA-based company which specializes in B Cell Medicines (BCMs), raised $92M in Series C funding.
The round was led by Nextech with existing investors including ARCH Venture Partners, Atlas Venture, RA Capital Management,... |
| 28.10.2024 | Be Biopharma: Pioneering the Future of Genetic Medicine with $82 Million in New Funding | In the ever-evolving landscape of biotechnology, Be Biopharma stands out like a lighthouse in a storm. This Cambridge, Massachusetts-based company has just secured $82 million in funding, a financial windfall that promises to propel its inn... |
| 25.10.2024 | Be Bio: $82 Million Raised To Discover And Develop Engineered B Cell Medicines | Be Biopharma – a leader in the discovery and development of engineered B Cell Medicines (BCMs) – announced key milestones alongside a new round of funding as its lead program BE-101 for Hemophilia B, enters the clinic, and its second develo... |
| 09.09.2024 | Пионер ксенотрансплантации eGenesis собрал $191 млн для генно-редактированных органов свиньи | Компания eGenesis уже попала в заголовки новостей благодаря трансплантации органов свиньи. В марте 2024 года eGenesis объявила о первой в мире успешной пересадке почки свиньи живому пациенту. Трансплантация была одобрена FDA в рамках расшир... |
| 04.09.2024 | eGenesis Raises $191M in Series B Funding | eGenesis, a Cambridge, MA-based biotechnology company developing human-compatible engineered organs to address the global organ shortage, raised $191M in Series B funding.
The round was led by Lux Capital, with participation from existing i... |
| 04.09.2024 | eGenesis: $191 Million (Series D) Secured To Develop Engineered Organs For Addressing Transplant Shortages | eGenesis, a biotechnology company that is developing human-compatible engineered organs to address the global organ shortage, announced today the closing of a $191 million Series D financing. The funding was led by Lux Capital, with partici... |
| 02.05.2024 | Transcarent raises $126M to accelerate AI capabilities | This round values the company at $2.2 billion
As everyone knows, the amount that the U.S. spends on healthcare is astronomical: in 2022 the number reached $4.4 trillion and it projected to reach $7.2 trillion in 2031, when it will account f... |
| 13.09.2022 | Novome gets $43.5M boost for its engineered microbiome therapies | Novome Biotechnologies — a South San Francisco-based biotech focused on genetically engineered microbial medicines (GEMMs) — raised $43.5 million in Series B funds on Tuesday.
The funding round was led by Tencent. Other investors — Universi... |
| 19.04.2022 | Free Market Health Secures $13.5M for Advance Specialty Pharmacy Ecosystem | What You Should Know:
Free Market Health, a Pittsburgh-based healthcare technology company transforming the specialty pharmacy ecosystem with a care-driven marketplace platform, today announced its $13.5M in Series A financing led by Alta P... |
| 11.01.2022 | Transcarent Raises $200M to Expand Care Platform for Self-Insured Employers | What You Should Know:
– Transcarent, a new and different health and care experience company for employees of self-insured employers and their families, today announced a $200M Series C round led by Kinnevik and Human Capital, with participa... |
| 03.03.2021 | DispatchHealth Management, LLC announced that it has received $200 million in funding from Tiger Global Management LLC, Alta Partners LP, Echo Health Ventures, Humana Inc., Oak HC/FT Partners LLC, Que... | On March 3, 2021, DispatchHealth Management, LLC closed the transaction. The transaction was led by new investor Tiger Global Management LLC, included participation from returning investors Alta Partners LP, Echo Health Ventures, Humana Inc... |
| 19.02.2021 | Alta Partners Closes NextGen Fund III, at $275M | Alta Partners, a San Francisco, CA and Denver, CO-based early-stage healthcare venture capital firm, closed Alta Partners NextGen Fund III, L.P., at $275m.
The firm’s limited partners include some of the leading healthcare organizations in ... |
| 24.06.2020 | Denver on-demand health care startup closes $136M Series C | Denver's DispatchHealth, a provider of tech-enabled in-home health care, announced the closing of $135.8 million growth capital financing Tuesday. It's one of the state's largest funding rounds in recent history.
The Series C round was led ... |
| 23.06.2020 | DispatchHealth Raises $135.8M to Expand On-Demand In-Home Care Model | What You Should Know
– Today DispatchHealth announced the closing of $135.8 million growth capital financing led by Optum Ventures and included participation from existing and new strategic investors.
– The additional funding enables Dispat... |
| 07.05.2019 | DispatchHealth Nabs $33M to Expand On-Demand Healthcare Model to High Acuity Patients | DispatchHealth (formerly known as True North Health Navigation), a Denver, CO-based provider of on-demand healthcare delivery to a patient’s home has raised $33 million in growth capital funding led by Echo Health Ventures, a strategic coll... |
| 26.08.2018 | NEA Leads $165M Funding for Paladina Health | Paladina Health, an innovative physician-access model of health care that improves patient care and satisfaction, today announced it has closed a $165 million growth equity funding round led by existing investor New Enterprise Associates (N... |
| 26.08.2018 | Oak HC/FT Joins $165M Funding for Paladina Health | Paladina Health, an innovative physician-access model of health care that improves patient care and satisfaction, today announced it has closed a $165 million growth equity funding round led by existing investor New Enterprise Associates (N... |
| 13.06.2018 | Term Sheet — Wednesday, June 13 | A WILD RIDE
Reports surfaced yesterday that Bird is raising even more capital. This time, the electric scooter company is looking at $200 million in venture funding at a $2 billion valuation. (Yes, this comes only two weeks after media repo... |
| 24.09.2017 | Questa Capital Leads $30.8M Funding for DispatchHealth | DispatchHealth, a Denver-based healthcare company offering on-demand, on-site healthcare services delivered in the home, senior care facility or office, today announced it has raised $30.8 million in growth financing. The investment is co-l... |
| 15.05.2017 | Alta Partners desembarca en España y lanza el fondo Alta Life Sciences Spain (Alta LS) | 15/05/2017
ALTA PARTNERS DESEMBARCA EN ESPAÑA Y LANZA EL FONDO ALTA LIFE SCIENCES SPAIN (ALTA LS).
Guy Nohra, cofundador de la entidad de capital riesgo (private equity) americana Alta Partners, desembarcó en Barcelona tras la asociación ... |
| 28.01.2017 | El inversor americano Alta Partners desembarca en Barcelona y lanza un fondo de ciencias de la vida | 28/01/2017
EL GRUPO INVERSOR AMERICANO ALTA PARTNERS DESEMBARCA EN BARCELONA Y LANZA UN FONDO DE CIENCIAS DE LA VIDA.
El grupo inversor con sede en San Francisco Alta Partners, referencia en el sector de ciencias de la vida, ha desembarca... |
| 30.09.2014 | Allakos Raises $10M in Funding | Allakos, a San Francisco Bay Area-based biotechnology company, raised an additional $10m in funding.
Backers included current investors Novo Ventures, Alta Partners, RiverVest Venture Partners and the Roche Venture Fund.
The company, which ... |
| 19.07.2013 | What’s special about the 3 biotechs in the top 10 for Q2 venture investments? | But let’s look a little more closely at the those three biotechnology companies and what they say about what is drawing investor attention. Two of the three provide valuable services to other life science companies. The third has a heart fa... |
| 08.05.2013 | Lumena Pharmaceuticals Secures $23M in Series A Financing | Lumena Pharmaceuticals, a San Diego, CA-based developer of oral therapeutics for rare liver diseases, secured $23m in Series A financing.
Backers included Pappas Ventures, which founded the company in 2011, RiverVest Venture Partners and Al... |
| 25.04.2013 | Esperion Therapeutics Raises $33M to Further Clinical Trials | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
The Ann Arbor-based biotech company Esperion Therapeutics announced today that it has completed a $33 million round of preferred stock financing. Longitude Capital led the rou... |
| 25.04.2013 | Esperion Therapeutics Completes $33M Financing | Esperion Therapeutics, Inc., a Plymouth, MI-based clinical stage biopharmaceutical company, completed a $33m financing.
The round was led by new investor Longitude Capital, with participation from existing investors Aisling Capital, Alta Pa... |
| 17.12.2012 | Allakos Completes $32M Series A Financing | Allakos Inc., a San Francisco Bay Area-based biotechnology company, has completed a $32m Series A financing.
The round was led by Novo Ventures with participation from Alta Partners, RiverVest Venture Partners and the Roche Venture Fund.
In... |
| 28.10.2012 | ZS Pharma Closes $46M Financing | ZS Pharma Inc., a Fort Worth, Texas-based specialty pharmaceutical company, has closed a $46m financing round.
The round was led by Alta Partners, with participation from new investors RiverVest Venture Partners, 3×5 Special Opportunity Par... |
| 30.04.2010 | ATS Medical backers stand to gain from Medtronic buyout | By Thomas Lee
ATS Medical Inc. (NSDQ:ATSI) stock has been a dog for quite a while, never rising above $5 a share since 2004 after posting a high of $20 a share nine years ago. But some investors stand to profit handsomely from Medtronic Inc... |
| 29.04.2010 | Select investors could make a killing on Medtronic/ATS Medical deal | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| 30.07.2009 | Pain treatment maker TorreyPines saved by Raptor merger | TorreyPines Therapeutics, maker of pain management medication, has skirted failure through a $1.4 million merger deal with Raptor Therapeutics. The deal dictates that Raptor will become a full subsidiary of TorreyPines, which is publicly tr... |
| 08.04.2009 | Aerovance inhales $38M for asthma drugs | Aerovance, developer of asthma medications, just brought in $38 million in a post-recapitalized third round of funding to push its lead drug candidate through a second phase of clinical trials. The company has already received $20 million, ... |
| 13.01.2009 | Sanarus raises $3M to battle breast cancer | Sanarus Medical, maker of a device used to diagnose and treat breast cancer, brought in $3 million in convertible note funding from existing investors, reports VentureWire. It’s currently working on a product that uses ultrasound technology... |
| 08.01.2009 | Dogster still has its bite despite the downturn | Dogster, the social network for dogs and their owners, just converted $425,000 in bridge funds into additional first-round financing, reports VentureWire. After a profitable 2008, raising a second round isn’t as pressing, the company says —... |
| 08.01.2009 | Plexxikon teams up with Roche, eyes $335M to fight kidney disease | Pharmaceutical company Plexxikon has joined forces with health care giant Roche for at least $60 million to develop a treatment for polycystic kidney disease, commonly called PKD. Under the terms of the deal, Roche will have full global rig... |
| 07.01.2009 | Intradigm closes $21.4M for cancer therapeutics | Biotech firm Intradigm has tacked an additional $2.9 million onto its second round of funding, bringing its total to $21.4 million. The new money will be used to advance its RNA interference-based line of therapeutics used to treat cancer.
... |
| 16.12.2008 | IPO market freezes out two more health care startups | Poor market conditions have dashed the IPO hopes of two more health care companies — clinical data provider Epocrates and cardiovascular drug developer Aegerion Pharmaecuticals. This makes 38 companies across all sectors that have had to pu... |
| 20.11.2008 | Arete nabs $16.7M more to treat metabolic disorders | Biotech company Arete Therapeutics brought in $16.7 million in the final tranche of a first round of funding that now totals $51 million. The Hayward, Calif.-based company will use the money to push its lead treatment for metabolic syndrome... |
| 17.11.2008 | Cancer drug developer ChemoCentryx cancels IPO | Mountain View, Calif.-based biotech firm ChemoCentryx announced that it withdrew its filing to go public, citing (as per usual) unfavorable market conditions. The company, which develops drugs to treat cancer and autoimmune ailments like Cr... |
| 04.11.2008 | Oracle scoops up Tacit’s intellectual property | Oracle announced yesterday that it has purchased intellectual property rights from Tacit Software for an undisclosed amount. The smaller, Palo Alto, Calif.-based company makes applications for sharing knowledge across companies.
Its Knowled... |
| 24.10.2008 | Phenomix cancels IPO, finds new lab partner | Biopharmaceuticals company Phenomix withdrew its filing to go public yesterday and right away announced a $340-million collaboration deal with Forest Laboratories. The IPO, intended to raise $86.3 million, had been pending since January.
Fo... |
| 03.10.2008 | Intradigm lands $18.5M to advance oncology treatment | Intradigm, a biotech company that develops RNA interference treatments for cancer, announced today that it took $18.5 million in a second round of financing that included new investors Lilly Ventures, Roche Venture Fund, MP Healthcare Ventu... |
| 15.08.2008 | Xelerated raises $13 million for fast networking chips | Xelerated, a maker of networking chip sets for carriers, has raised a $13 million round from its existing investors.
Sixth Swedish National Pension Fund led the round. Others included Accel Partners, Alta Partners, Amadeus Capital Partners ... |
| 20.11.2007 | Agami raising $50 million — for yet another storage company | Agami, a Silicon Valley storage company with high-profile venture backing, is doing what any self-respecting company in the sector should do these days: Raise a large amount of money before the opportunity melts away.
The company confirmed ... |
| 13.08.2007 | Life sciences briefing: Monday, Aug. 13, 2007 | (UPDATED: See below.)
Featured companies: FoldRx Pharmaceuticals, Ophthotech, Pevion Biotech, Restoration Robotics, Glide Pharma, Reliant Pharmaceuticals, Nanosphere, SurModics, BioFX Laboratories
FoldRx Pharma to receive $22M against cysti... |
| 12.07.2007 | Agensys pulls in $41M for cancer drugs | Santa Monica, Calif.-based Agensys, a biotech focused on new cancer drugs, raised $41 million in a fourth funding round. Duquesne Capital Management and JAFCO led the round, joined by Innovis Investments, Nextech Venture, Bear Stearns Healt... |
| 29.06.2007 | Paracor raises $44M for heart-failure device that restrains the heart | (UPDATED: See below.) Paracor Medical, a Sunnyvale, Calif., startup developing a mesh restraint designed to support failing hearts, raised $44.35 million in a fourth round of funding. The company is vying with another device startup, Acorn ... |
| 26.06.2007 | Ceregene: Catching an updraft in gene therapy | (UPDATED: See below.)
Ceregene, a San Diego biotech at work on a gene therapy for Parkinson’s disease, has so far raised $28 million in a third funding round and last week struck a development partnership with Genzyme that resulted in a $25... |
| 23.05.2007 | Arete raises $35M for cardiovascular treatments | Arete Therapeutics, a Hayward, Calif., developer of biotech cardiovascular treatments, raised a $35 million extension to its first round of funding. Founded in 2003, the company is working on “small molecule” drugs that target a metabolism-... |
| 08.05.2007 | Cardiovascular biotech Portola Pharmaceuticals raises $70M, eyes IPO | Portola Pharmaceuticals, a South San Francisco, Calif., biotech aiming to develop treatments for blood clots and other heart-related problems, raised $70 million in a third round of financing dominated by late-stage and public-market invest... |
| 09.10.2006 | Alta Partners has raised $500M fund | Alta Partners has raised $500 million for its eighth venture fund, according to VentureWire (sub required).
It is one more sign that venture money continues go flood the valley, despite move last week by valley venture firm Sevin Rosen to r... |
| - | Select investors could make a killing on Medtronic/ATS Medical deal | ATS Medical Inc. (NASDAQ:ATSI) stock has been a dog for quite a while, never rising above $5 a share since 2004. Yet some investors stand to profit handsomely from Medtronic Inc.’s (NYSE:MDT) proposed $370 million acquisition of the company... |
| - | What’s special about the 3 biotechs in the top 10 for Q2 venture investments? | Cellular engineering, precision medicine, and using G protein-coupled receptors to treat heart failure and other conditions. That’s the focus of the three biotechnology companies that made the top 10 for venture investment deals last quarte... |
